Share on Pinterest Ozempic, the active ingredient of which is semaglutide, can also reduce the risk of heart disease, according to research. Steve Christo – Corbis/Corbis via Getty Images ...

While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in ...

Among patients who experienced an early cardiovascular event, those treated with semaglutide had approximately 40% fewer ...

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

As research continues, the role of semaglutide in cardiovascular care will likely expand, potentially transforming how we approach heart disease prevention in at-risk populations. With heart ...

In this randomized controlled trial, oral semaglutide significantly reduced the risk of adverse cardiovascular events in ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related ...